$1.550
+0.020 (+1.31%)收盤時
AUTL 資訊
AUTL 事件
Autolus Therapeutics Files to Sell 3.5M American Depositary Shares
Autolus Therapeutics files to sell 3.5M American Depositary Shares for holders
Autolus Therapeutics Receives FDA RMAT Designation
Autolus Therapeutics announced that the FDA has granted regenerative medicine advanced therapy, or RMAT, designation to obecabtagene autoleucel for the treatment of systemic lupus erythematosus and lupus nephritis.
Autolus Raises 2026 AUCATZYL Revenue Guidance to $140M-$150M
Coonsensus $139.42M. The company said, "Autolus recently increased the full year 2026 guidance for AUCATZYL net product revenue to $140 million to $150 million, from between $120 million to $135 million. Based on current operating plans, including anticipated AUCATZYL net revenues and proceeds of the combined first and second tranches totaling $100 million from the recently-announced credit facility, Autolus expects that its current and projected cash, cash equivalents and marketable securities will be sufficient to fund the Company's operations into Q2 2028."
Autolus Q2 Revenue Reaches $45.69M, Exceeds Expectations
Reports Q2 revenue $45.69M, consensus $40.15M. "In the second quarter we achieved substantial sales growth in the ongoing AUCATZYL launch, driven by physician enthusiasm and expanding product use within existing authorized treatment centers, as well as the addition of new centers coming online. We believe this adoption is testament to the product's efficacy and differentiated safety profile, which was underscored by the ROCCA consortium real world data reported earlier in the year," said Christian Itin, Chief Executive Officer of Autolus. "The increased product volumes, combined with the ongoing operational efficiency initiatives announced in April, together drove a significant step up in gross margin. We expect improvement over time towards our peak estimate for adult ALL margins of 65-70%."
Autolus AUCATZYL Sales Surge Over 70%
"In the second quarter, AUCATZYL sales increased approximately 70% over Q1 2026 and more than 100% compared to Q2 2025. The strong sales growth is driven by expanding product use within existing authorized treatment centers, as well as the addition of new centers coming online. Physician adoption of AUCATZYL is underscored by the real-world experience reported by the ROCCA consortium earlier in the year," said Dr. Christian Itin, Chief Executive Officer of Autolus. "The increased product volumes, combined with the ongoing operational efficiency initiatives announced in April 2026, together drove a significant step up in gross margin from a negative gross margin of approximately 20% in the second half of 2025 to a positive gross margin of approximately 35% in the first half of 2026. We expect gross margin to continue to improve."
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。